Screening potomků osob s časnou manifestací ICHS - editorial

Jan Bruthans

Vnitr Lek 2017, 63(6):380-381 | DOI: 10.36290/vnl.2017.077  

Je konečně na řadě primární prevence kardiovaskulárních onemocnění? - editorial

Eliška Sovová

Vnitr Lek 2017, 63(6):382-383 | DOI: 10.36290/vnl.2017.078  

Význam metabolitů vitaminu D a správnost jejich stanovení - editorial

Radovan Bílek

Vnitr Lek 2017, 63(6):384-385  

Testikulární lymfomy - editorial

Vít Procházka

Vnitr Lek 2017, 63(6):386 | DOI: 10.36290/vnl.2017.080  

Trombóza a malignita - editorial

Debora Karetová

Vnitr Lek 2017, 63(6):387-388  

Predictors of quality of life in Czech female breast cancer survivors following treatment with special interest to coping strategies

Jiří Jarkovský, Kateřina Skřivanová, Klára Benešová, Lenka Šnajdrová, Jakub Gregor, Hana Peterková, Marcela Bendová, Dagmar Brančíková, Nela Elfmarková, Tomáš Svěrák, Ľubomíra Anderková, Luboš Minář, Markéta Protivánková, Jan Nedvěd, Ladislav Dušek, Lydia Temoshok

Vnitr Lek 2017, 63(6):389-396 | DOI: 10.36290/vnl.2017.082  

Objectives:This study examined the prognostic significance of breast cancer patients' characteristics (coping strategies, BMI, age) and disease characteristics (stage of disease, relapse) with respect to quality of life (QoL) following treatment. Sample and settings:120 breast cancer patients following treatment were recruited. Health-related QoL was assessed using the Czech version of FACT-B and SF-36; additionally, we used a life satisfaction questionnaire. Coping strategies were assessed using the SVF-78 method. In our sample of women, the average time from diagnosis to start of the study was 5.3 years. Statistical...

Risk factors for cardiovascular diseases in the descendants of patients after early myocardial infarction

Markéta Mateřánková, Petra Karnosová, Jitka Mlíková Seidlerová, Jan Filipovský, Otto Mayer jr

Vnitr Lek 2017, 63(6):398-402 | DOI: 10.36290/vnl.2017.083  

Goal:The cardiovascular diseases (CVDs) developing as the result of atherosclerosis are among the most frequent causes of morbidity and mortality within the Czech Republic and elsewhere. Genetic predisposition for cardiovascular diseases is amplified in the presence of routine risk factors which can be influenced. Our aim was to establish whether the level of the risk factors for ICHS already differs in the population of healthy descendants of the patients after early myocardial infarction, as opposed to the control group of examined individuals. Methodology:We approached adult children (n = 127; age 28.7 ± 6.5 years)...

"Snags" connected with establishing the vitamin D

Anton Vaňuga, Peter Huba, Ivana Ságová, Pavel Blažíček, Jarmila Melegová, Juraj Payer, Peter Vaňuga

Vnitr Lek 2017, 63(6):403-408 | DOI: 10.36290/vnl.2017.084  

Objective:The aim of proposed paper was to compare a three total 25-hydroxy-vitamin D immunoassays to that of HPLC with UV detection. Material and methods:Serum 25-(OH) D levels were measured from blood samples of 109 patients with different immunoassays (ABBOTT, ROCHE, SIEMENS) and method of HPLC which was chosen as the reference. In the first step immunoassays were compared to HPLC. In the second step immunoassays were compared to each other. Further purpose of methods comparison the Passing-Bablok regression and Bland-Altman analysis were used. The limits of maximum acceptable differences were set at 21.5 %, according to...

Clinical study FOURIER

Ján Murín

Vnitr Lek 2017, 63(6):411-414 | DOI: 10.36290/vnl.2017.085  

A new group of hypolipidemic substances, i.e. PCSK9 protein inhibitors, is now coming into use in clinical practice, to what extent a high residual cardiovascular risk remains also in patients treated with statins. The FOURIER study (Further cardiovascular OUtcomes Research with PCSK9 Inhibition subjects with Elevated Risk) is the first "event" study which has shown that evolocumab (PCSK9 antibody) further significantly reduces serum LDL cholesterol and subsequently also cardiovascular morbidity and mortality: (a) composite primary goal (cardiovascular mortality, incidence of heart attacks, strokes, hospitalizations for unstable angina, coronary revascularization)...

Primary testicular lymphoma

Monika Motyčková, Vladimíra Vosáhlová, David Belada, Martin Šimkovič, Pavel Žák

Vnitr Lek 2017, 63(6):415-422 | DOI: 10.36290/vnl.2017.086  

Primary testicular lymphoma (PTL) is a rare form of extranodal lymphoma and accounts for approximately 1 to 2 % of all non-Hodgkin's lymphoma and 5 % of testicular malignancies. PTL typically affects patients older than 60 years. The most common clinical symptom is painless scrotal swelling. The ultrasound of testicles followed by orchiectomy and histological and imunohistochemical examinations are the most important tools for diagnostic assessment. Diffuse large B cell lymphoma (DLBCL) is the most common histological type of PTL. Orchiectomy is an important part of the treatment, which includes the combination of systemic imunochemotherapy and prophylactic...

Rivaroxaban in high-risk patients

Jindřich Špinar, Lenka Špinarová

Vnitr Lek 2017, 63(6):424-430 | DOI: 10.36290/vnl.2017.087  

Blockade of factor Xa becomes a routine part of clinical practice instead of vitamin K blockade with warfarin, providing a more beneficial and safer effect. The main indications are prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism. Rivaroxaban has the largest number of data across high risk patients. Rivaroxaban is an oral selective anti Xa inhibitor with well predictive pharmacokinetics and pharmacodynamics. It inhibits thrombin formation for 24 hours, is well absorbed and biological availability is 80-100 %. The excretion is mainly renal and the mean elimination...

Two perspectives on venous thromboembolism in oncology

Patrik Palacka, Jana Hirmerová

Vnitr Lek 2017, 63(6):431-440 | DOI: 10.36290/vnl.2017.088  

An increased risk of venous thromboembolism (VTE) in patients with malignancy compared with the current population is determined by risk factors including the use of anticancer treatments, in particular some hormonal drugs, cytostatics, vascular endothelial growth factor (VEGF) inhibitors and epidermal receptor growth factor (EGFR) inhibitors, immunomodulators, and erythropoietins. The population of cancer patients is divided into a group of individuals with a history of malignant disease in complete remission and patients with active (locally advanced or metastatic) malignant disease in terms of approach to VTE.Venous thromboembolism negatively...

Insulin pump in type 2 diabetes: B-cell focused treatment

Klára Picková, Zdeněk Rušavý

Vnitr Lek 2017, 63(6):441-445 | DOI: 10.36290/vnl.2017.089  

Type 2 diabetes is a disorder characterized by insulin resistance and progressive deterioration of B-cell insulin secretion. B-cell protective strategies for lowering glucolipotoxicity by rapid achievement of normoglycemia using exogenous insulin improve their function and prolong diabetes remission. Insulin pump is an effective treatment method in newly diagnosed diabetes, where even short-term pump therapy is B-cell protective. Combination therapy with insulin pump and antidiabetics targeting the incretin system acts in synergy to protect the B-cell. While the positive effect of insulin pump is apparent even a year after stopping the therapy, the...

Pavel Jansa, Michael Aschermann et al. Chronická plicní hypertenze

Radek Pudil

Vnitr Lek 2017, 63(6):452  

Sedlář M et al. Zlomeniny proximálního femuru. Komplexní péče o pacienta

Tomáš Trč

Vnitr Lek 2017, 63(6):453  

Zeman P et al. Artroskopie kyčelního kloubu

Tomáš Trč

Vnitr Lek 2017, 63(6):453  

Kovalová S, Nečas J. 3D echokardiografie … pro začátečníky i pokročilé

Lubomír Elbl

Vnitr Lek 2017, 63(6):455  

Kardiovaskulární mortalita u diabetu

Jan Škrha jr, Jan Škrha

Vnitr Lek 2017, 63(6):447-449 | DOI: 10.36290/vnl.2017.090  

Účinnost a bezpečnost dabigatranu při podávání dle SPC a evropských doporučení. Komentář k článku Patient outcomes using the European label for dabigatran

Petr Janský

Vnitr Lek 2017, 63(6):450-451